Every Form 4 that Alaunos Therapeutics, Inc. (TCRT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TCRT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TCRT filings page.
Alaunos Therapeutics, Inc. reported that CEO Holger Weis received a grant of common stock as part of his compensation. On 2026-08-06, he acquired 4,363 shares of common stock at a value of $2.01 per share, issued in lieu of net salary. Following this stock issuance, Weis directly owns 25,483 shares of Alaunos Therapeutics common stock.
Jerman Michael Allen reported acquisition or exercise transactions in this Form 4 filing.
Alaunos Therapeutics, Inc. reported that director Michael Allen Jerman received a grant of 8,138 shares of common stock on 2026-07-23, valued at $1.92 per share. The shares were issued in lieu of board fees and increase his direct holdings to 23,759 shares.
Alaunos Therapeutics, Inc. CEO Holger Weis received a grant of 4,568 shares of common stock on 2026-07-23 at $1.92 per share, issued in lieu of net salary. After this compensation-related acquisition, he directly holds 21,120 common shares.
Robert W. Postma, a director of Alaunos Therapeutics, Inc., reported the acquisition of 8,463 shares of common stock on 23 July 2026 at $1.92 per share, described as shares issued in lieu of board fees. Following this grant, he holds 58,609 shares directly and additional indirect holdings of 24 shares through his spouse's IRA and 62,416 shares through WaterMill Asset Management Corp.
Vieser Jaime reported acquisition or exercise transactions in this Form 4 filing.
Alaunos Therapeutics, Inc. director Jaime Vieser reported an equity compensation grant of 8,789 shares of common stock on 2026-07-23, valued at $1.92 per share and issued in lieu of board fees. Following this award, he holds 47,642 shares directly. The report also lists indirect holdings of 2,100 shares held by his children and 13,503 shares held by Brushwood LLC, where he serves as Manager.
Alaunos Therapeutics Chief Executive Officer Holger Weis received a stock grant as compensation. On June 30, 2026, he acquired 3,880 shares of Alaunos common stock at $2.26 per share in a grant issued in lieu of net salary. Following this award, he directly holds 16,552 common shares, and no derivative positions are reported in this filing.
Alaunos Therapeutics Chief Executive Officer Holger Weis reported a stock-based compensation transaction. On June 12, 2026, he acquired 7,761 shares of Alaunos common stock at $2.26 per share as a grant categorized as a "grant, award, or other acquisition." A footnote explains these shares were issued in lieu of net salary, indicating they are compensation rather than an open‑market purchase. Following this award, Weis directly holds 12,672 common shares of Alaunos Therapeutics.
Weis Holger reported acquisition or exercise transactions in this Form 4 filing.
Alaunos Therapeutics, Inc. reported that Chief Executive Officer Holger Weis received a stock-based compensation grant. On May 22, 2026, he was issued 3,700 shares of common stock at $2.37 per share in lieu of net salary. Following this award, Weis directly holds 4,911 shares of Alaunos common stock. This transaction is classified as a grant or award rather than an open-market purchase or sale.
Vieser Jaime reported acquisition or exercise transactions in this Form 4 filing.
Alaunos Therapeutics director Jaime Vieser reported an equity award. Vieser received a grant of 6,515 shares of Alaunos Therapeutics common stock at a price of $2.59 per share, increasing his directly held stake to 38,853 shares.
In addition to these direct holdings, the filing lists 13,503 shares held indirectly through Brushwood LLC, where Vieser is the manager, and 2,100 shares held indirectly for the benefit of his children.
Postma Robert W reported acquisition or exercise transactions in this Form 4 filing.
Alaunos Therapeutics director Robert W. Postma reported a stock-based compensation grant. On April 29, 2026, he received 6,274 shares of Alaunos Therapeutics common stock at $2.59 per share, issued in lieu of board fees. Following this grant, he directly holds 50,146 shares of common stock.
In addition to his direct holdings, Postma has indirect ownership interests, including 62,416 shares held by WaterMill Asset Management Corp., where he serves as principal, and 24 shares held in his spouse’s IRA. The filing does not show any open-market purchases or sales, only this compensation-related award and updated ownership positions.
Alaunos Therapeutics, Inc. director Michael Allen Jerman received a grant of 6,032 shares of common stock on April 29, 2026, as a stock award issued in lieu of board fees. Following this compensation-related acquisition, he directly holds a total of 15,621 shares of Alaunos common stock.
Alaunos Therapeutics, Inc. director Jerman Michael Allen reported receiving 5,406 shares of common stock on 01/12/2026 at $2.89 per share. According to the filing, these shares were issued in lieu of cash board fees, meaning the director took stock as compensation for board service. Following this transaction, he beneficially owns 9,589 shares of Alaunos common stock, held directly.
Alaunos Therapeutics director Robert W. Postma received 5,622 shares of common stock on January 12, 2026, as compensation in lieu of board fees at a price of $2.89 per share. Following this grant, he directly holds 43,872 Alaunos shares. He also reports indirect beneficial ownership of 24 shares through his spouse's IRA and 62,416 shares held by WaterMill Asset Management Corp., where he serves as principal.
Alaunos Therapeutics director Jaime Vieser reported receiving additional company stock as compensation. On January 12, 2026, Vieser acquired 5,839 shares of Alaunos Therapeutics common stock at $2.89 per share, described as shares issued in lieu of board fees. After this transaction, Vieser directly holds 32,338 common shares.
Vieser also reports indirect holdings of Alaunos common stock, including 2,100 shares held by the reporter’s children and 13,503 shares held by Brushwood LLC, an entity for which Vieser is the manager. The filing classifies Vieser as a director and indicates the form is filed by one reporting person.